dipyridamole has been researched along with Colitis Gravis in 1 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The implications of these results might partly explain the high variability in bioavailability in vivo, assuming that most of the observed variability is due to the absorption, and not the elimination, process." | 1.42 | Inter-subject variability in intestinal drug solubility. ( Basit, AW; Flanagan, T; Martin, PD; Rabbie, SC, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rabbie, SC | 1 |
| Flanagan, T | 1 |
| Martin, PD | 1 |
| Basit, AW | 1 |
1 other study available for dipyridamole and Colitis Gravis
| Article | Year |
|---|---|
Inter-subject variability in intestinal drug solubility.
Topics: Administration, Oral; Biological Availability; Buffers; Colitis, Ulcerative; Dipyridamole; Furosemid | 2015 |